IU presents an excellent environment for the development of a NGVL. The institution has built a strong gene therapy program with over eleven NIH-funded researchers pursuing clinical gene therapy. The close collaborative efforts of the gene therapy investigators has led to the successful competition for two program projects and the designation as a Centers of Excellence in Molecular Hematology. A Vector Production Facility is currently funded as a core for two existing program grants. The applicants are proposing to expand the current facility to provide viral vectors to outside investigators as a member of the NGVL. The NGVL at IU will: 1) provide a mechanism for review, generation and distribution of clinical grade vector to investigators in the gene therapy field; 2) generate vector producer cell lines and supernate intended for clinical use; 3) certify vectors for clinical use based on Food and Drug Administration (FDA) guidelines under good manufacturing practice (GMP) and good laboratory practice (GLP) specifications; and 4) provide regulatory support for investigators using vectors generated in the NGVL.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Materials Resource Cooperative Agreements (U42)
Project #
Application #
Study Section
Special Emphasis Panel (SRC (03))
Program Officer
Knazek, Richard
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Indiana University-Purdue University at Indianapolis
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Moullier, Philippe; Snyder, Richard O (2012) Recombinant adeno-associated viral vector reference standards. Methods Enzymol 507:297-311
Cornetta, Kenneth; Yao, Jing; Jasti, Aparna et al. (2011) Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther 19:557-66
Lock, Martin; McGorray, Susan; Auricchio, Alberto et al. (2010) Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther 21:1273-85
Peters, B; Dirscherl, S; Dantzer, J et al. (2008) Automated analysis of viral integration sites in gene therapy research using the SeqMap web resource. Gene Ther 15:1294-8
Moullier, Philippe; Snyder, Richard O (2008) International efforts for recombinant adeno-associated viral vector reference standards. Mol Ther 16:1185-8
Cornetta, Kenneth; Reeves, Lilith; Cross, Scott (2008) Production of retroviral vectors for clinical use. Methods Mol Biol 433:17-32
Jin, Qingwen; Marsh, Jon; Cornetta, Kenneth et al. (2008) Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. J Gen Virol 89:2611-21
Zhang, Shangming; Joseph, Guiandre; Pollok, Karen et al. (2006) G2 cell cycle arrest and cyclophilin A in lentiviral gene transfer. Mol Ther 14:546-54
Cornetta, K; Matheson, L; Ballas, C (2005) Retroviral vector production in the National Gene Vector Laboratory at Indiana University. Gene Ther 12 Suppl 1:S28-35
Kahl, Christoph A; Pollok, Karen; Haneline, Laura S et al. (2005) Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses: variable transduction related to cell type and culture conditions. Mol Ther 11:470-82

Showing the most recent 10 out of 21 publications